What 1cBio does

1cBio, Inc. is a privately held, clinical-stage biotechnology company founded in 2022 and headquartered at 236 West Portal Avenue, #159, San Francisco, California. The company develops precision small-molecule therapeutics across oncology and rare disease, anchored by three pipeline programs: OC-1/ALE1, a first-in-class oral small molecule for hypophosphatasia (HPP); OC-3, a next-generation PARP1-selective inhibitor designed to maximize efficacy while minimizing the hematologic toxicities associated with non-selective PARP inhibitors; and a series of CDK7 inhibitors active against parental and drug-resistant solid tumors, including a brain-penetrant candidate with potential in palbociclib-resistant and brain-metastatic breast cancer. The OC-1/ALE1 asset is licensed worldwide to Alesta Therapeutics under a December 2024 agreement; OC-3 is being positioned for regional partnership(s) to support clinical development.

1cBio's discovery platform combines medicinal chemistry and translational sciences with external clinical and basic-science collaborators, producing a scalable, tailored discovery engine. Differentiation rests on rational mechanism selection (validated DDR and HPP targets), deliberate selectivity profiles (PARP1 over PARP2 sparing, brain-penetrant CDK7), and programs engineered to preempt acquired or intrinsic resistance. The company is led by CEO Andrew Protter, Ph.D., who led preclinical research on XTANDI and TALZENNA at Medivation and previously drove an AI-assisted discovery program at Auransa; co-founder Son Pham serves as VP of Chemistry, CFO Prashant Jain has overseen finance since inception, and an industry-experienced board oversees governance.

As a pre-commercial biotech, 1cBio generates no product revenue; economic activity consists of milestone and royalty entitlements plus monthly FTE compensation from Alesta Therapeutics under the OC-1/ALE1 license. No public funding rounds, institutional investor ownership, or revenue figures have been disclosed. Customer-facing assets are targeted at healthcare providers treating HPP and oncology patients with HR-deficient or HR-proficient tumors of the breast, prostate, ovary, or pancreas, though all end-customer access is achieved through the Alesta partnership rather than direct commercialization. Headcount is reported at 1-10 employees as of the available data.

Name

1cBio

Legal name

1cBio, Inc.

Website

https://1cbio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

1cBio is a privately held, clinical-stage San Francisco biotech developing precision small-molecule drug candidates for hypophosphatasia (OC-1/ALE1, licensed to Alesta Therapeutics), oncology (OC-3 PARP1-selective inhibitor), and CDK7-driven solid tumors, using a medicinal chemistry and translational sciences discovery platform.

Ownership category

akta.pro rank

Product category

Precision Medicine Drug Discovery

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

akta.pro secondary industries

Nonclinical Study Management & Regulatory Writing (IND-enabling) (HLAGAFAN), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Precision medicine drug discovery
• Small molecule inhibitors
• Oncology therapeutics development
• PARP1 selective inhibitors
• Hypophosphatasia treatment

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels2 records

Marketing channels2 records

Core offering

1cBio is a precision-medicine biotechnology company that discovers and develops proprietary small-molecule drug candidates, with its most advanced programs being OC-1/ALE1 (a first-in-class, orally bioavailable therapy for hypophosphatasia, partnered worldwide with Alesta Therapeutics) and OC-3 (a next-generation PARP1-selective inhibitor for prostate, ovarian and breast cancers), along with brain-penetrant CDK7 inhibitors for solid tumors. The company combines medicinal chemistry and translational sciences to design molecules that address validated mechanisms while preemptively countering acquired or intrinsic resistance.

Product overview

1cBio is a precision medicine biotech company developing a portfolio of small molecule drug candidates. Its most advanced program is OC-1/ALE1 (first-in-class for hypophosphatasia, partnered with Alesta Therapeutics), alongside OC-3 (best-in-class selective PARP1 inhibitor for multiple cancers), and CDK7 inhibitors (for solid tumors including brain-penetrant formulations for resistant breast cancer). The programs target DDR-related pathways for both HR deficient and HR proficient tumors.

Differentiator

Problem solved

Functional benefit

Products and services

• OC-1/ALE1 First-in-class, orally bioavailable small molecule therapeutic for hypophosphatasia (HPP), a rare genetic disorder of defective bone mineralization. Licensed worldwide to Alesta Therapeutics (December 2024) for development and commercialization, with 1cBio retaining milestones, royalties and equity.
• OC-3 Next-generation, potentially best-in-class PARP1-selective inhibitor for prostate, ovarian and breast cancers, designed to maximize efficacy while avoiding significant hematologic toxicities exhibited by non-selective PARP inhibitors, with moderate PARP1 trapping and predicted PARP2 sparing at therapeutic exposures.
• CDK7 Inhibitors Small-molecule CDK7 inhibitors for solid tumors effective against both parental and drug-resistant cancer cell lines, including a potent and brain-penetrant CDK7 inhibitor active across breast cancer phenotypes (including palbociclib-resistant breast cancer) with potential applicability to breast cancer patients with brain metastasis.

Quantifiable outcome

• Phase 1/2a clinical data for HPP program expected by H2 2026

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Alesta TherapeuticscoreStrategic or Co-development Partner · 1 December 2024Worldwide licensing agreement for OC-1/ALE1 development and commercialization signed December 2024. 1cBio is entitled to traditional milestones and royalties, as well as equity ownership in Alesta and monthly compensation for FTE support. The partnership enabled OC-1/ALE1 to enter clinical development in 2025, with initial Phase 1/2a data in HPP patients expected by H2 2026.

Recent moves7 records

Expansion highlights4 records

Direct peers

• Black Diamond Therapeutics: Black Diamond Therapeutics is a clinical-stage precision oncology company developing small molecules against oncogenic driver mutations — comparable to 1cBio as a discovery-stage precision medicine biotech with a focus on differentiated mechanisms in oncology.
• Erasca: Erasca is a clinical-stage precision oncology company developing kinase inhibitors targeting the RAS/MAPK pathway — comparable to 1cBio as a small molecule precision oncology biotech with multiple programs and a focus on validated cancer targets.
• Theseus Pharmaceuticals: Theseus Pharmaceuticals is a precision oncology biotech developing small molecule kinase inhibitors (including a pan-RAF inhibitor THE-630) targeting resistance mutations — comparable to 1cBio's approach of developing differentiated small molecules against validated oncology targets with resistance-countering design.
• Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage precision oncology company developing small molecule drugs targeting chromatin remodeling and transcription — comparable to 1cBio as a similarly-staged precision medicine biotech with a differentiated small molecule platform.
• Relay Therapeutics: Relay Therapeutics is a clinical-stage precision medicine company applying computational approaches to develop small molecule oncology drugs against validated targets — comparable to 1cBio as a precision medicine biotech developing differentiated small molecules for oncology.
• Revolution Medicines: Revolution Medicines is a clinical-stage precision oncology company developing targeted small molecule inhibitors of RAS and other oncogenic drivers — comparable to 1cBio as a discovery-to-clinical precision medicine biotech targeting validated oncology mechanisms.
• Syros Pharmaceuticals: Syros Pharmaceuticals is a clinical-stage precision medicine company developing CDK7 inhibitors (SY-5609 and SY-1365) for solid tumors and hematologic malignancies — directly comparable to 1cBio's CDK7 program targeting drug-resistant cancers.
• Prelude Therapeutics: Prelude Therapeutics is a clinical-stage precision oncology company developing small molecule inhibitors (including PRMT5 and MCL1 inhibitors) — comparable to 1cBio as a similarly-sized, similarly-staged precision medicine biotech developing targeted small molecules for oncology.

Broad incumbents

• AstraZeneca (Alexion): AstraZeneca owns Alexion, which markets STRENSIQ (asfotase alfa), the only approved treatment for hypophosphatasia (HPP). Directly comparable to 1cBio as the incumbent therapy provider for the disease OC-1/ALE1 targets — represents both the competitive threat and the established market opportunity.
• Pfizer (Medivation): Pfizer acquired Medivation and now markets TALZENNA (talazoparib), an approved PARP inhibitor for prostate and breast cancers. Directly comparable to 1cBio's OC-3 program given TALZENNA is a current standard-of-care PARP inhibitor that OC-3 aims to differentiate against with improved PARP1-selectivity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/1cbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 1cBio